Cargando…
The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669792/ https://www.ncbi.nlm.nih.gov/pubmed/38002051 http://dx.doi.org/10.3390/biomedicines11113051 |
_version_ | 1785149253530681344 |
---|---|
author | Altabas, Velimir Marinković Radošević, Jelena Špoljarec, Lucija Uremović, Stella Bulum, Tomislav |
author_facet | Altabas, Velimir Marinković Radošević, Jelena Špoljarec, Lucija Uremović, Stella Bulum, Tomislav |
author_sort | Altabas, Velimir |
collection | PubMed |
description | Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative properties. EPCs are mononuclear cells that are derived from different tissues. Circulating EPCs contribute to regenerating the vessel’s intima and restoring vascular function. The ability of EPCs to repair vascular damage depends on their number and functionality. Diabetic patients have a decreased circulating EPC count and impaired EPC function. This may at least partially explain the increased risk of diabetic complications, including the increased cardiovascular risk in these patients. Recent studies have confirmed that many currently available drugs with proven cardiovascular benefits have beneficial effects on EPC count and function. Among these drugs are also medications used to treat different types of diabetes. This manuscript aims to critically review currently available evidence about the ways anti-diabetic treatment affects EPC biology and to provide a broader context considering cardiovascular complications. The therapies that will be discussed include lifestyle adjustments, metformin, sulphonylureas, gut glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor analogs, sodium-glucose transporter 2 inhibitors, and insulin. |
format | Online Article Text |
id | pubmed-10669792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106697922023-11-14 The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells Altabas, Velimir Marinković Radošević, Jelena Špoljarec, Lucija Uremović, Stella Bulum, Tomislav Biomedicines Review Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative properties. EPCs are mononuclear cells that are derived from different tissues. Circulating EPCs contribute to regenerating the vessel’s intima and restoring vascular function. The ability of EPCs to repair vascular damage depends on their number and functionality. Diabetic patients have a decreased circulating EPC count and impaired EPC function. This may at least partially explain the increased risk of diabetic complications, including the increased cardiovascular risk in these patients. Recent studies have confirmed that many currently available drugs with proven cardiovascular benefits have beneficial effects on EPC count and function. Among these drugs are also medications used to treat different types of diabetes. This manuscript aims to critically review currently available evidence about the ways anti-diabetic treatment affects EPC biology and to provide a broader context considering cardiovascular complications. The therapies that will be discussed include lifestyle adjustments, metformin, sulphonylureas, gut glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor analogs, sodium-glucose transporter 2 inhibitors, and insulin. MDPI 2023-11-14 /pmc/articles/PMC10669792/ /pubmed/38002051 http://dx.doi.org/10.3390/biomedicines11113051 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Altabas, Velimir Marinković Radošević, Jelena Špoljarec, Lucija Uremović, Stella Bulum, Tomislav The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title | The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title_full | The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title_fullStr | The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title_full_unstemmed | The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title_short | The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells |
title_sort | impact of modern anti-diabetic treatment on endothelial progenitor cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669792/ https://www.ncbi.nlm.nih.gov/pubmed/38002051 http://dx.doi.org/10.3390/biomedicines11113051 |
work_keys_str_mv | AT altabasvelimir theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells AT marinkovicradosevicjelena theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells AT spoljareclucija theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells AT uremovicstella theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells AT bulumtomislav theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells AT altabasvelimir impactofmodernantidiabetictreatmentonendothelialprogenitorcells AT marinkovicradosevicjelena impactofmodernantidiabetictreatmentonendothelialprogenitorcells AT spoljareclucija impactofmodernantidiabetictreatmentonendothelialprogenitorcells AT uremovicstella impactofmodernantidiabetictreatmentonendothelialprogenitorcells AT bulumtomislav impactofmodernantidiabetictreatmentonendothelialprogenitorcells |